Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence
- PMID: 36200921
- PMCID: PMC10078143
- DOI: 10.1111/dth.15903
Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence
Abstract
Skin aging goes beyond a chronological process and also results from extrinsic factors referred to as the exposome. Hyaluronic acid (HA) is an important component of the extracellular matrix, with loss starting at 25 years old. While many studies of HA concern topical use, few literature reviews only address the use of topical HA in dermatology. This review describes the different characteristics of HA-containing cosmeceuticals, with a focus on skin aging and the impact of exposome factors on HA synthesis and degradation. A review was performed using the terms HA, hyaluronan, topical, dermatology, cosmetic, aging treatment, exposome, and cosmeceuticals. Results are also presented from a recent randomized controlled trial (RCT), which investigated the additional benefit of using a HA epidermic filler (HA-filler serum) combined with Botulinum toxin type A (BoNTA) to treat signs of skin aging. Subjects were randomized to two groups: HA-filler serum starting 24 h after the BoNTA injection then twice daily for 24 weeks, or the control group, which received BoNTA. HA is a key ingredient used in cosmeceuticals for its hydration/antiaging properties (hygroscopic, rheological, and viscoelastic). Several clinical studies indicate that HA is both well tolerated and effective, adjuvant to both post-surgical and facial rejuvenation procedures. In the RCT, one of few studies to combine BoNTA and HA with a 6-month follow-up, the HA-filler serum lengthened the duration of BoNTA's effect in reducing wrinkles. Numerous studies support HA-based cosmeceuticals as a noninvasive, effective solution for improving skin hydration and rejuvenation.
Keywords: cosmeceutical; dermatology; hyaluronic acid; skin; topical application.
© 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
Conflict of interest statement
Dr. Bravo is a paid consultant for L'Oréal Brasil. Priscila Correia, José Euzébio Gonçalves Junior and Beatriz Sant'Anna are employees of L'Oréal Brazil, and Dr. Delphine Kerob is an employee of L'Oréal Paris, the manufacturer of the formulation under study.
Figures
References
-
- Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomark Prev. 2005;14(8):1847‐1850. - PubMed
-
- Kasprzak D, Wnorowski A. A variety of processes that affect the perception of skin aging. Curr Issues Pharm Med Sci. 2019;32(3):146‐153.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
